AHMEDABAD: Homegrown pharma major, Torrent Pharmaceuticals Limited posted Rs 287 crore in profit for the fourth quarter of the fiscal year 2022-23, the company said on Tuesday in its stock exchange filing. Torrent Pharma posted a net loss of Rs 118 crore during the corresponding period.
During the full fiscal year 2022-23, its net profit reached Rs 1,245 crore, up 60% against Rs 777 crore in the previous fiscal.
The board of the pharma company also recommended a dividend of Rs 8 per share, subject to the shareholders’ approval. The company's revenue rose to Rs 2,491 crore for the fourth quarter compared to Rs 2,131 crore in the year-ago period, Torrent Pharma said in a statement.
The flagship company of the Torrent Group, Torrent Pharma, is among the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS), Vitamins Minerals Nutritionals (VMN), and Cosmo-Dermatology and is ranked 6th in the Indian pharmaceuticals industry.
The company’s share price closed on the BSE at Rs 1,717.15 a piece, up by 0.69% against the previous close of Rs 1,705.40.
Stay updated with the latest news on Times of India. Don't miss daily games like Crossword, Sudoku, and Mini Crossword. Spread love this holiday season with these Christmas wishes, messages, and quotes.
Start a Conversation
Post comment